content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on October 15, 2021</B></P>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 1pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: right"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ADIAL PHARMACEUTICALS, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(Exact name of registrant as specified in its charter)</I></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><I>&nbsp;</I></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; font: 11pt Calibri,sans-serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="text-align: center; font: 11pt Calibri,sans-serif; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; font: 11pt Calibri,sans-serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>82-3074668</B></FONT></TD></TR>
    <TR>
      <TD STYLE="font: 11pt Calibri,sans-serif; text-align: center"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><I>(State or other jurisdiction of<BR>
  incorporation or organization)</I></FONT></TD>
      <TD STYLE="text-align: center; font: 11pt Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center">
      <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(I.R.S. Employer No.)</I></P>
      <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>1180 Seminole Trail, Suite 495<BR>
  Charlottesville, Virginia 22901<BR>
  (434) 422-9800</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(Address, including ZIP code, and telephone number, including
  area code, of registrant&rsquo;s principal executive office)</I></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(Full title of the Plan)</I></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>William B. Stilley</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>President and Chief Executive Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Adial Pharmaceuticals, Inc.<BR>
  1180 Seminole Trail, Suite 495<BR>
  Charlottesville, Virginia 22901<BR>
  (434) 422-9800</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(Name, address and telephone number of agent for service)</I></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>with copies to:</I></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Leslie Marlow, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Hank Gracin, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Patrick J. Egan, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Gracin &amp; Marlow, LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>The Chrysler Building</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>405 Lexington Avenue, 26<SUP>th</SUP>&nbsp;Floor</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>New York, New York 10174</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(212) 907-6457</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(Name, address and telephone number)</I></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
  &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth
  company&rdquo; in Rule 12b-2 of the Exchange Act.:</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 65%; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Large accelerated filer &nbsp;&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="width: 35%; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Accelerated
  filer &nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Non-accelerated filer &nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Smaller reporting company &nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Emerging growth company &nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Calibri,sans-serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman,serif">If an emerging
  growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
  new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 6pt"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman,serif; text-align: left">Title of Securities to be Registered</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman,serif; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Amount<BR>
  to be<BR> Registered(1)(2)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman,serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman,serif; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Proposed<BR> Maximum<BR> Aggregate<BR> Offering Price<BR> Per Share(3)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman,serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman,serif; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Proposed<BR> Maximum<BR> Aggregate<BR> Offering Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman,serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman,serif; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Amount of<BR> Registration Fee(4)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman,serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 52%; font: 10pt Times New Roman,serif; text-align: left">Common Stock, par value $0.001 per share, under the 2017 Equity Incentive Plan, as amended</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman,serif; text-align: right"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">2,000,000&nbsp;shares</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman,serif; text-align: right">3.72</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman,serif; text-align: right">7,440,100</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman,serif; text-align: right">689.70</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 1pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">The
  securities to be registered include options and rights to acquire the common stock of Adial Pharmaceuticals, Inc.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Pursuant
  to Rule 416(a) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), this registration statement also covers
  any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated
                                              pursuant to Rule 457(c) and 457(h) of the Securities Act solely for purposes of calculating
                                              the registration fee. The price per share is based upon the average of the high and low prices
                                              of the common stock on October 12, 2021, as reported by the NASDAQ Capital Market.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Calculated
  under Section 6(b) of the Securities Act as 0.00009270 of the proposed maximum aggregate offering price.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 6pt"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  
  
  <P STYLE="font: 10pt Times New Roman,serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; text-align: center; margin-top: 0; margin-bottom: 6pt"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Adial Pharmaceuticals, Inc. (the &ldquo;Registrant&rdquo;
  or the &ldquo;Company&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) its Registration Statement
  on Form S-8 (Registration No. 333-226884) on August 16, 2018 (the &ldquo;2018 Registration Statement&rdquo;) pursuant to and in accordance
  with the requirements of General Instruction E to Form S-8 for the purpose of registering under the Securities Act of 1933, as amended
  (the &ldquo;Securities Act&rdquo;), 1,750,000 shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), to
  be offered and sold under the Registrant&rsquo;s 2017 Equity Incentive Plan (hereinafter referred to as the &ldquo;Plan&rdquo;).&nbsp;&nbsp;Pursuant
  to General Instruction E to Form S-8, the contents of the 2018 Registration Statement are incorporated into this Registration Statement
  by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-233760) on September 13, 2019 (the
  &ldquo;2019 Registration Statement&rdquo;) pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 1,750,000 shares of Common Stock to be offered and sold under the Plan.&nbsp;&nbsp;These
  additional 1,750,000 shares of Common Stock were added pursuant to the adoption of Amendment No. 1 to the Plan. &nbsp;Pursuant to General
  Instruction E to Form S-8, the contents of the 2019 Registration Statement are incorporated into this Registration Statement by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-248759) on September 11, 2020 (the
  &ldquo;2020 Registration Statement&rdquo;) pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 2,000,000 shares of Common Stock to be offered and sold under the Plan.&nbsp;&nbsp;These
  additional 2,000,000 shares of Common Stock were added pursuant to the adoption of Amendment No. 2 to the Plan. &nbsp;Pursuant to General
  Instruction E to Form S-8, the contents of the 2020 Registration Statement are incorporated into this Registration Statement by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the Registrant is filing
  this Registration Statement on Form S-8 (the &ldquo;Registration Statement&rdquo;) to register an additional 2,000,000 shares of Common
  Stock that were added to the Plan by a vote of the Registrant&rsquo;s stockholders at the Registrant&rsquo;s 2021 Annual Meeting of Stockholders,
  which was held on September 27, 2021. <FONT STYLE="background-color: white">These additional 2,000,000 shares of Common Stock were added
  pursuant to the adoption of Amendment No. 3 to the Plan. The aggregate number of shares of Common Stock that may be issued under the Plan,
  as amended, is 7,500,000 shares. &nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><B>PART I</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The information specified in Item 1 and
  Item 2 of Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428
  under the Securities Act, and the introductory note to Part I of Form S-8. The documents containing the information specified in Part
  I will be delivered to the participants in the Plan as required by Rule 428(b)(1). Such documents and the documents incorporated by reference
  in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that
  meets the requirements of Section 10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Securities and Exchange Commission
  (the &ldquo;Commission&rdquo;) allows the Registrant to &ldquo;incorporate by reference&rdquo; the information it files with it which
  means that it can disclose important information to you by referring you to those documents instead of having to repeat the information
  in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that
  the Registrant files with the Commission will automatically update and supersede this information. The Registrant incorporates by reference
  the documents listed below and any future filings made with the Commission under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange
  Act between the date of this prospectus and the termination of the offering:</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt; background-color: white">Our Annual Report on </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021017009/f10k2020_adialpharmaceutical.htm">Form 10-K</A></FONT> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt; background-color: white">for the fiscal year ended December 31, 2020 filed with the SEC on March 22, 2021 (File No. 001-38323);</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Our Quarterly Report on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021027140/f10q0321_adialpharma.htm">May 17, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021042118/f10q0621_adialpharma.htm">August 12, 2021</A>, respectively;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Our
      Current Reports on Form 8-K filed with the SEC on </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021005850/ea134337-8k_adialpharma.htm">February
      1, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021009037/ea135514-8k_adialpharm.htm">February
      12, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021011956/ea136450-8k_adialpharm.htm">February
      26, 2021</A></FONT> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(other than as indicated therein), </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021015275/ea137623-8k_adialpharma.htm">March
      15, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021020935/ea139311-8k_adialpharma.htm">April
      9, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021030853/ea142213-8k_adialpharm.htm">June
      4, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021033650/ea143133-8k_adialpharm.htm">June
      23, 2021</A></FONT> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(other than as indicated therein), </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021034036/ea143298-8k_adial.htm">June
      25, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021035692/ea143752-8k_adialpharma.htm">July
      6, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021036263/ea143883-8k_adialpharma.htm">July
      9, 2021</A></FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021037166/ea144326-8k_adialphar.htm">July
      16, 2021</A></FONT> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(other than as indicated therein), <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021040445/ea145268-8k_adial.htm">August
      5, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021045799/ea146718-8k_adialpharma.htm">August 31,
      2021</A> (other than as indicated therein) <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1513525/000121390021050629/ea147995-8k_adial.htm">September 29, 2021</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1513525/000121390021051650/ea148504-8k_adial.htm">October 6, 2021</A> (File No. 001-38323); and <FONT STYLE="background-color: white">&nbsp;</FONT></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021044137/def14a0821_adialpharm.htm">Schedule 14A</A> filed with the SEC on August 23, 2021, as amended by the filing of a revised Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021045165/ea146534-defr14a_adialpharma.htm">Schedule 14A</A> (DEFR14A) on August 27, 2021; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt; background-color: white">The
      description of our common stock set forth in (i) our registration statements on</FONT> <FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017013072/f8a12b110617_adialpharma.htm">Form
      8-A12B</A><FONT STYLE="background-color: white">, filed with the SEC on December 11, 2017 and Form </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390018009518/f8a12b070618a1_adialphar.htm">8-A12B/A</A> <FONT STYLE="background-color: white">filed
      with the SEC on July 23, 2018 (File No. 001-38323) and (ii)&nbsp;</FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021017009/f10k2020ex4-19_adialpharmac.htm">Exhibit&nbsp;4.19</A><FONT STYLE="background-color: white">&mdash;Description
      of Securities to our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021017009/f10k2020_adialpharmaceutical.htm">Form 10-K</A> for the fiscal year ended December 31, 2020 filed with the SEC on March 22, 2021
      (File No. 001-38323).</FONT></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">All reports and other documents subsequently
  filed by the Company pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed to be incorporated by reference
  in this Registration Statement and to be a part of this Registration Statement from the respective date of filing of each of those reports
  or documents until the filing of a post-effective amendment to this Registration Statement which indicates either that all securities
  offered by this Registration Statement have been sold or which deregisters all of the securities under this Registration Statement then
  remaining unsold.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Any statement contained in this Registration
  Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be
  modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement
  or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement
  modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded,
  to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item 4. Description of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in">The class of securities to be offered is registered under Section
  12 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item&nbsp;5. Interests of Named Experts and Counsel.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item&nbsp;6. Indemnification of Directors and Officers.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Registrant is incorporated under the
  laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify
  any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether
  civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact
  that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation
  as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo;
  fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
  suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed
  to the corporation&rsquo;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that
  his or her conduct was illegal except that no indemnification is permitted without judicial approval if the officer or director is adjudged
  to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred
  to above, the corporation must indemnify him or her against the expenses (including attorneys&rsquo; fees) actually and reasonably incurred.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Registrant&rsquo;s certificate of
  incorporation and bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware
  General Corporation Law.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 102(b)(7) of the Delaware General
  Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally
  liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability
  for any:</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">transaction
  from which the director derives an improper personal benefit;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">act
  or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">unlawful
  payment of dividends or redemption of shares; or</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">breach
  of a director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Registrant&rsquo;s certificate of
  incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding
  in advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking, by or on behalf of such director
  or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be
  indemnified by the Registrant.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 174 of the Delaware General Corporation
  Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful
  stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved
  or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes
  of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of
  the unlawful acts.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As permitted by the Delaware General Corporation
  Law, the Registrant has entered into indemnity agreements with each of its directors and executive officers, that require the Registrant
  to indemnify such persons against any and all costs and expenses (including attorneys&rsquo;, witness or other professional fees) actually
  and reasonably incurred by such persons in connection with any action, suit or proceeding (including derivative actions), whether actual
  or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director or officer or
  is or was acting or serving as an officer, director, employee or agent of the Registrant or any of its affiliated enterprises. Under these
  agreements, the Registrant is not required to provide indemnification for certain matters, including:</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">indemnification
  beyond that permitted by the Delaware General Corporation Law;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">indemnification
  for any proceeding with respect to the unlawful payment of remuneration to the director or officer;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD>
      <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">indemnification for certain proceedings involving a final judgment
  that the director or officer is required to disgorge profits from the purchase or sale of the Registrant&rsquo;s stock;</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD>
      <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">indemnification for proceedings involving a final judgment that the
  director&rsquo;s or officer&rsquo;s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct
  or a breach of his or her duty of loyalty, but only to the extent of such specific determination;</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD>
      <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">indemnification for proceedings or claims brought by an officer or
  director against us or any of the Registrant&rsquo;s directors, officers, employees or agents, except for claims to establish a right
  of indemnification or proceedings or claims approved by the Registrant&rsquo;s board of directors or required by law;</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">indemnification for settlements the director or officer enters into without the Registrant&rsquo;s consent; or</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">indemnification in violation of any undertaking required by the Securities Act or in any registration statement filed by the Registrant.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The indemnification agreements also set
  forth certain procedures that will apply in the event of a claim for indemnification thereunder.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Registrant has an insurance policy
  in place that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities
  Act or otherwise.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item 7. Exemption from Registration Claimed.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR>
      <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid">
      <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Exhibit No.</B></P></TD>
      <TD STYLE="vertical-align: top; width: 1%; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">3.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017010930/fs12017a2ex3-3_adial.htm">Certificate of Incorporation of Adial Pharmaceuticals, Inc. (1)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">3.2</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017010930/fs12017a2ex3-6_adial.htm">Bylaws of Adial Pharmaceuticals, Inc. (1)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390018011309/fs82018ex4-1_adialpharma.htm">Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (2)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390019018002/fs82019ex4-2_adialpharma.htm">Amendment No. 1 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (3)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.3</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017009468/fs12017ex4-12_adialpharma.htm">Form of Stock Option Grant Notice, Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) and Notice of Exercise under the 2017 Equity Incentive Plan (4)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.4</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390020026280/ea126600ex4-4_adialpharma.htm">Amendment No. 2 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (5)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.5</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021050629/ea147995ex10-1_adial.htm">Amendment No. 3 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (6)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">5.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="ea148381ex5-1_adial.htm">Opinion of Gracin &amp; Marlow, LLP regarding Legality of Shares (7)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">23.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="ea148381ex23-1_adial.htm">Consent of Friedman LLP, Independent Registered Public Accounting Firm (7)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">23.2</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="ea148381ex5-1_adial.htm">Consent of Gracin &amp; Marlow, LLP (contained in Exhibit 5.1) (7)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">24.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="#a_001">Power of Attorney (included on the signature page of this registration statement) (7)</A></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 1pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-1, as amended (File No. 333-220368), filed with the Commission on October 25, 2017.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-8 (File No. 333-226884) filed with the Commission on August 16, 2018.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-8 (File No. 333-233760) filed with the Commission September 13, 2019.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-1, as amended (File No. 333-220368), filed with the Commission on September 7, 2017.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-8 (File No. 333-248759) filed with the Commission September 11, 2020.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Current Report on Form 8-K (File No. <FONT STYLE="background-color: white">001-38323</FONT>) filed
  with the Commission September 29, 2021.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Filed
  herewith</FONT></TD>
  </TR></TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B></B></P>
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item&nbsp;9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">The
  undersigned Registrant hereby undertakes:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">To
  include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">To
  reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information in the Registration Statement;
  and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">To
  include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
  material change to such information in the Registration Statement;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">provided, however, that paragraphs
  (a)(1)(i) and (a)(1)(ii) of this section do not apply to the Registration Statement on Form S-8 if the information required to be included
  in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant
  pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">The
  undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
  Registrant&rsquo;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act that is incorporated by reference
  in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
  offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission
  such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that
  a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
  officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
  officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
  the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Charlottesville, Virginia, on the 15<SUP>th</SUP> day of October, 2021.&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 11pt">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>ADIAL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 60%; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 5%; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 35%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ William B. Stilley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">William B. Stilley</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Title:</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="a_001"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the undersigned, whose signature
  appears below, hereby constitutes and appoints each of William Stilley and Joseph Truluck, act singly, as his true and lawful attorney-in-fact
  and agent, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities, to
  sign any or all amendments to this Registration Statement, whether pre-effective or post-effective, and to file the same with all exhibits
  thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact
  and agent, or his substitute full power and authority to do and perform each and every act and thing necessary or appropriate to be done
  with respect to this Registration Statement or any amendments hereto in the premises, as fully to all intents and purposes as he might
  or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, or
  any of them, may lawfully do or cause to be done by virtue thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the date indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 11pt">
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="width: 1%; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 46%; border-bottom: black 1.5pt solid; text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 1%; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ William B. Stilley</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Chief Executive Officer and President</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">William B. Stilley</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">October 15, 2021</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ Joseph M. Truluck</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Chief Operating Officer and Chief Financial Officer</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Joseph M. Truluck</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">October 15, 2021</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ J. Kermit Anderson</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">J. Kermit Anderson</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">October 15, 2021</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ Roberson H. Gilliland</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Robertson H. Gilliland</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">October 15, 2021</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ Tony Goodman</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Tony Goodman</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">October 15, 2021</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid">
      <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman,serif; margin: 0">/s/ James W. Newman</P></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">James W. Newman, Jr.</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">October 15, 2021</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ Kevin Schuyler</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Kevin Schuyler, CFA</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Member of the Board of Directors</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: center; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">October 15, 2021</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EXHIBIT INDEX</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
    <TR>
      <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid">
      <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Exhibit No.</B></P></TD>
      <TD STYLE="vertical-align: top; width: 1%; font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">3.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017010930/fs12017a2ex3-3_adial.htm">Certificate of Incorporation of Adial Pharmaceuticals, Inc. (1)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">3.2</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017010930/fs12017a2ex3-6_adial.htm">Bylaws of Adial Pharmaceuticals, Inc. (1)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390018011309/fs82018ex4-1_adialpharma.htm">Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (2)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390019018002/fs82019ex4-2_adialpharma.htm">Amendment No. 1 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (3)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.3</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390017009468/fs12017ex4-12_adialpharma.htm">Form of Stock Option Grant Notice, Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) and Notice of Exercise under the 2017 Equity Incentive Plan (4)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.4</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390020026280/ea126600ex4-4_adialpharma.htm">Amendment No. 2 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (5)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.5</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1513525/000121390021050629/ea147995ex10-1_adial.htm">Amendment No. 3 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (6)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">5.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="ea148381ex5-1_adial.htm">Opinion of Gracin &amp; Marlow, LLP regarding Legality of Shares (7)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">23.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="ea148381ex23-1_adial.htm">Consent of Friedman LLP, Independent Registered Public Accounting Firm (7)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">23.2</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="ea148381ex5-1_adial.htm">Consent of Gracin &amp; Marlow, LLP (contained in Exhibit 5.1) (7)</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">24.1</FONT></TD>
      <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><A HREF="#a_001">Power of Attorney (included on the signature page of this registration statement) (7)</A></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 1pt Times New Roman,serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-1, as amended (File No. 333-220368), filed with the Commission on October 25, 2017.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-8 (File No. 333-226884) filed with the Commission on August 16, 2018.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-8 (File No. 333-233760) filed with the Commission September 13, 2019.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-1, as amended (File No. 333-220368), filed with the Commission on September 7, 2017.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Form S-8 (File No. 333-248759) filed with the Commission September 11, 2020.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Incorporated
  by reference to the Registrant&rsquo;s Current Report on Form 8-K (File No. <FONT STYLE="background-color: white">001-38323</FONT>) filed
  with the Commission September 29, 2021.</FONT></TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Filed
  herewith</FONT></TD>
  </TR></TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT>&nbsp;</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0">7</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B></B></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea148381-s8_adialpharma.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 102905}]
metadata_filer: {"company-data": {"conformed-name": "ADIAL PHARMACEUTICALS, INC.", "cik": "0001513525", "assigned-sic": "2834", "irs-number": "800667150", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-260304", "film-number": "211326824"}, "business-address": {"street1": "1180 SEMINOLE TRAIL", "street2": "SUITE 495", "city": "CHARLOTTESVILLE", "state": "VA", "zip": "22901", "phone": "434-422-9800"}, "mail-address": {"street1": "1180 SEMINOLE TRAIL", "street2": "SUITE 495", "city": "CHARLOTTESVILLE", "state": "VA", "zip": "22901"}, "former-company": [{"former-conformed-name": "ADial Pharmaceuticals, L.L.C.", "date-changed": "20170515"}, {"former-conformed-name": "Adial Pharmaceuticals, L.L.C.", "date-changed": "20110218"}]}
text: As filed with the Securities and Exchange Commission
  on October 15, 2021
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  ADIAL PHARMACEUTICALS, INC.
  (Exact name of registrant as specified in its charter)
  Delaware
  82-3074668
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer No.)
  Identification Number)
  1180 Seminole Trail, Suite 495
  Charlottesville, Virginia 22901
  (434) 422-9800
  (Address, including ZIP code, and telephone number, including
  area code, of registrant's principal executive office)
  ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN
  (Full title of the Plan)
  William B. Stilley
  President and Chief Executive Officer
  Adial Pharmaceuticals, Inc.
  1180 Seminole Trail, Suite 495
  Charlottesville, Virginia 22901
  (434) 422-9800
  (Name, address and telephone number of agent for service)
  with copies to:
  Leslie Marlow, Esq.
  Hank Gracin, Esq.
  Patrick J. Egan, Esq.
  Gracin & Marlow, LLP
  The Chrysler Building
  405 Lexington Avenue, 26
  th
  Floor
  New York, New York 10174
  (212) 907-6457
  (Name, address and telephone number)
  Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
  "large accelerated filer," "accelerated filer" "smaller reporting company" and "emerging growth
  company" in Rule 12b-2 of the Exchange Act.:
  Large accelerated filer
  ☐
  Accelerated
  filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☒
  If an emerging
  growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
  new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
  ☐
  CALCULATION OF REGISTRATION FEE
  Title of Securities to be Registered
  Amount
  to be
  Registered(1)(2)
  Proposed
  Maximum
  Aggregate
  Offering Price
  Per Share(3)
  Proposed
  Maximum
  Aggregate
  Offering Price
  Amount of
  Registration Fee(4)
  Common Stock, par value $0.001 per share, under the 2017 Equity Incentive Plan, as amended
  2,000,000 shares
  $
  3.72
  $
  7,440,100
  $
  689.70
  (1)
  The
  securities to be registered include options and rights to acquire the common stock of Adial Pharmaceuticals, Inc.
  (2)
  Pursuant
  to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers
  any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction.
  (3)
  Estimated
                                              pursuant to Rule 457(c) and 457(h) of the Securities Act solely for purposes of calculating
                                              the registration fee. The price per share is based upon the average of the high and low prices
                                              of the common stock on October 12, 2021, as reported by the NASDAQ Capital Market.
  (4)
  Calculated
  under Section 6(b) of the Securities Act as 0.00009270 of the proposed maximum aggregate offering price.
  EXPLANATORY NOTE
  Adial Pharmaceuticals, Inc. (the "Registrant"
  or the "Company") filed with the Securities and Exchange Commission (the "Commission") its Registration Statement
  on Form S-8 (Registration No. 333-226884) on August 16, 2018 (the "2018 Registration Statement") pursuant to and in accordance
  with the requirements of General Instruction E to Form S-8 for the purpose of registering under the Securities Act of 1933, as amended
  (the "Securities Act"), 1,750,000 shares of common stock, par value $0.001 per share (the "Common Stock"), to
  be offered and sold under the Registrant's 2017 Equity Incentive Plan (hereinafter referred to as the "Plan").  Pursuant
  to General Instruction E to Form S-8, the contents of the 2018 Registration Statement are incorporated into this Registration Statement
  by reference.
  The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-233760) on September 13, 2019 (the
  "2019 Registration Statement") pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 1,750,000 shares of Common Stock to be offered and sold under the Plan.  These
  additional 1,750,000 shares of Common Stock were added pursuant to the adoption of Amendment No. 1 to the Plan.  Pursuant to General
  Instruction E to Form S-8, the contents of the 2019 Registration Statement are incorporated into this Registration Statement by reference.
  The
  Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-248759) on September 11, 2020 (the
  "2020 Registration Statement") pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for
  the purpose of registering under the Securities Act an additional 2,000,000 shares of Common Stock to be offered and sold under the Plan.  These
  additional 2,000,000 shares of Common Stock were added pursuant to the adoption of Amendment No. 2 to the Plan.  Pursuant to General
  Instruction E to Form S-8, the contents of the 2020 Registration Statement are incorporated into this Registration Statement by reference.
  In addition, the Registrant is filing
  this Registration Statement on Form S-8 (the "Registration Statement") to register an additional 2,000,000 shares of Common
  Stock that were added to the Plan by a vote of the Registrant's stockholders at the Registrant's 2021 Annual Meeting of Stockholders,
  which was held on September 27, 2021.
  These additional 2,000,000 shares of Common Stock were added
  pursuant to the adoption of Amendment No. 3 to the Plan. The aggregate number of shares of Common Stock that may be issued under the Plan,
  as amended, is 7,500,000 shares.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  The information specified in Item 1 and
  Item 2 of Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428
  under the Securities Act, and the introductory note to Part I of Form S-8. The documents containing the information specified in Part
  I will be delivered to the participants in the Plan as required by Rule 428(b)(1). Such documents and the documents incorporated by reference
  in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that
  meets the requirements of Section 10(a) of the Securities Act.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  The Securities and Exchange Commission
  (the "Commission") allows the Registrant to "incorporate by reference" the information it files with it which
  means that it can disclose important information to you by referring you to those documents instead of having to repeat the information
  in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that
  the Registrant files with the Commission will automatically update and supersede this information. The Registrant incorporates by reference
  the documents listed below and any future filings made with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Exchange
  Act between the date of this prospectus and the termination of the offering:
  ●
  Our Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2020 filed with the SEC on March 22, 2021 (File No. 001-38323);
  ●
  Our Quarterly Report on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021 filed with the SEC on
  May 17, 2021
  and
  August 12, 2021
  , respectively;
  ●
  Our
      Current Reports on Form 8-K filed with the SEC on
  February
      1, 2021
  ,
  February
      12, 2021
  ,
  February
      26, 2021
  (other than as indicated therein),
  March
      15, 2021
  ,
  April
      9, 2021
  ,
  June
      4, 2021
  ,
  June
      23, 2021
  (other than as indicated therein),
  June
      25, 2021
  ,
  July
      6, 2021
  ,
  July
      9, 2021
  ,
  July
      16, 2021
  (other than as indicated therein),
  August
      5, 2021
  ,
  August 31,
      2021
  (other than as indicated therein)
  September 29, 2021
  and
  October 6, 2021
  (File No. 001-38323); and
  ●
  Our Definitive Proxy Statement on
  Schedule 14A
  filed with the SEC on August 23, 2021, as amended by the filing of a revised Definitive Proxy Statement on
  Schedule 14A
  (DEFR14A) on August 27, 2021; and
  ●
  The
      description of our common stock set forth in (i) our registration statements on
  Form
      8-A12B
  , filed with the SEC on December 11, 2017 and Form
  8-A12B/A
  filed
      with the SEC on July 23, 2018 (File No. 001-38323) and (ii)
  Exhibit 4.19
  —Description
      of Securities to our Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2020 filed with the SEC on March 22, 2021
      (File No. 001-38323).
  All reports and other documents subsequently
  filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed to be incorporated by reference
  in this Registration Statement and to be a part of this Registration Statement from the respective date of filing of each of those reports
  or documents until the filing of a post-effective amendment to this Registration Statement which indicates either that all securities
  offered by this Registration Statement have been sold or which deregisters all of the securities under this Registration Statement then
  remaining unsold.
  Any statement contained in this Registration
  Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be
  modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement
  or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement
  modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded,
  to constitute a part of this Registration Statement.
  1
  Item 4. Description of Securities.
  The class of securities to be offered is registered under Section
  12 of the Exchange Act.
  Item 5. Interests of Named Experts and Counsel.
  Not applicable.
  Item 6. Indemnification of Directors and Officers.
  The Registrant is incorporated under the
  laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify
  any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether
  civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact
  that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation
  as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys'
  fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
  suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed
  to the corporation's best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that
  his or her conduct was illegal except that no indemnification is permitted without judicial approval if the officer or director is adjudged
  to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred
  to above, the corporation must indemnify him or her against the expenses (including attorneys' fees) actually and reasonably incurred.
  The Registrant's certificate of
  incorporation and bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware
  General Corporation Law.
  Section 102(b)(7) of the Delaware General
  Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally
  liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability
  for any:
  ●
  transaction
  from which the director derives an improper personal benefit;
  ●
  act
  or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
  ●
  unlawful
  payment of dividends or redemption of shares; or
  ●
  breach
  of a director's duty of loyalty to the corporation or its stockholders.
  The Registrant's certificate of
  incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding
  in advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking, by or on behalf of such director
  or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be
  indemnified by the Registrant.
  Section 174 of the Delaware General Corporation
  Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful
  stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved
  or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes
  of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of
  the unlawful acts.
  2
  As permitted by the Delaware General Corporation
  Law, the Registrant has entered into indemnity agreements with each of its directors and executive officers, that require the Registrant
  to indemnify such persons against any and all costs and expenses (including attorneys', witness or other professional fees) actually
  and reasonably incurred by such persons in connection with any action, suit or proceeding (including derivative actions), whether actual
  or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director or officer or
  is or was acting or serving as an officer, director, employee or agent of the Registrant or any of its affiliated enterprises. Under these
  agreements, the Registrant is not required to provide indemnification for certain matters, including:
  ●
  indemnification
  beyond that permitted by the Delaware General Corporation Law;
  ●
  indemnification
  for any proceeding with respect to the unlawful payment of remuneration to the director or officer;
  ●
  indemnification for certain proceedings involving a final judgment
  that the director or officer is required to disgorge profits from the purchase or sale of the Registrant's stock;
  ●
  indemnification for proceedings involving a final judgment that the
  director's or officer's conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct
  or a breach of his or her duty of loyalty, but only to the extent of such specific determination;
  ●
  indemnification for proceedings or claims brought by an officer or
  director against us or any of the Registrant's directors, officers, employees or agents, except for claims to establish a right
  of indemnification or proceedings or claims approved by the Registrant's board of directors or required by law;
  ●
  indemnification for settlements the director or officer enters into without the Registrant's consent; or
  ●
  indemnification in violation of any undertaking required by the Securities Act or in any registration statement filed by the Registrant.
  The indemnification agreements also set
  forth certain procedures that will apply in the event of a claim for indemnification thereunder.
  The Registrant has an insurance policy
  in place that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities
  Act or otherwise.
  3
  Item 7. Exemption from Registration Claimed.
  Not applicable.
  Item 8. Exhibits.
  Exhibit No.
  Description
  3.1
  Certificate of Incorporation of Adial Pharmaceuticals, Inc. (1)
  3.2
  Bylaws of Adial Pharmaceuticals, Inc. (1)
  4.1
  Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (2)
  4.2
  Amendment No. 1 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (3)
  4.3
  Form of Stock Option Grant Notice, Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) and Notice of Exercise under the 2017 Equity Incentive Plan (4)
  4.4
  Amendment No. 2 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (5)
  4.5
  Amendment No. 3 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (6)
  5.1
  Opinion of Gracin & Marlow, LLP regarding Legality of Shares (7)
  23.1
  Consent of Friedman LLP, Independent Registered Public Accounting Firm (7)
  23.2
  Consent of Gracin & Marlow, LLP (contained in Exhibit 5.1) (7)
  24.1
  Power of Attorney (included on the signature page of this registration statement) (7)
  (1)
  Incorporated
  by reference to the Registrant's Form S-1, as amended (File No. 333-220368), filed with the Commission on October 25, 2017.
  (2)
  Incorporated
  by reference to the Registrant's Form S-8 (File No. 333-226884) filed with the Commission on August 16, 2018.
  (3)
  Incorporated
  by reference to the Registrant's Form S-8 (File No. 333-233760) filed with the Commission September 13, 2019.
  (4)
  Incorporated
  by reference to the Registrant's Form S-1, as amended (File No. 333-220368), filed with the Commission on September 7, 2017.
  (5)
  Incorporated
  by reference to the Registrant's Form S-8 (File No. 333-248759) filed with the Commission September 11, 2020.
  (6)
  Incorporated
  by reference to the Registrant's Current Report on Form 8-K (File No.
  001-38323
  ) filed
  with the Commission September 29, 2021.
  (7)
  Filed
  herewith
  4
  Item 9. Undertakings.
  (a)
  The
  undersigned Registrant hereby undertakes:
  (1)
  To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  To
  include any prospectus required by Section 10(a)(3) of the Securities Act;
  (ii)
  To
  reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information in the Registration Statement;
  and
  (iii)
  To
  include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
  material change to such information in the Registration Statement;
  provided, however, that paragraphs
  (a)(1)(i) and (a)(1)(ii) of this section do not apply to the Registration Statement on Form S-8 if the information required to be included
  in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant
  pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
  (2)
  That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.
  (3)
  To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.
  (b)
  The
  undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
  Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference
  in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
  offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  (c)
  Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission
  such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that
  a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
  officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
  officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
  the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  5
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Charlottesville, Virginia, on the 15
  th
  day of October, 2021.
  ADIAL PHARMACEUTICALS, INC.
  By:
  /s/ William B. Stilley
  Name:
  William B. Stilley
  Title:
  President and Chief Executive Officer
  POWER OF ATTORNEY
  Each of the undersigned, whose signature
  appears below, hereby constitutes and appoints each of William Stilley and Joseph Truluck, act singly, as his true and lawful attorney-in-fact
  and agent, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities, to
  sign any or all amendments to this Registration Statement, whether pre-effective or post-effective, and to file the same with all exhibits
  thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact
  and agent, or his substitute full power and authority to do and perform each and every act and thing necessary or appropriate to be done
  with respect to this Registration Statement or any amendments hereto in the premises, as fully to all intents and purposes as he might
  or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, or
  any of them, may lawfully do or cause to be done by virtue thereof.
  Pursuant to the requirements of the Securities
  Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the date indicated.
  Signature
  Title
  Date
  /s/ William B. Stilley
  Chief Executive Officer and President
  William B. Stilley
  (Principal Executive Officer)
  October 15, 2021
  /s/ Joseph M. Truluck
  Chief Operating Officer and Chief Financial Officer
  Joseph M. Truluck
  (Principal Financial and Accounting Officer)
  October 15, 2021
  /s/ J. Kermit Anderson
  J. Kermit Anderson
  Member of the Board of Directors
  October 15, 2021
  /s/ Roberson H. Gilliland
  Robertson H. Gilliland
  Member of the Board of Directors
  October 15, 2021
  /s/ Tony Goodman
  Tony Goodman
  Member of the Board of Directors
  October 15, 2021
  /s/ James W. Newman
  James W. Newman, Jr.
  Member of the Board of Directors
  October 15, 2021
  /s/ Kevin Schuyler
  Kevin Schuyler, CFA
  Member of the Board of Directors
  October 15, 2021
  6
  EXHIBIT INDEX
  Exhibit No.
  Description
  3.1
  Certificate of Incorporation of Adial Pharmaceuticals, Inc. (1)
  3.2
  Bylaws of Adial Pharmaceuticals, Inc. (1)
  4.1
  Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (2)
  4.2
  Amendment No. 1 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (3)
  4.3
  Form of Stock Option Grant Notice, Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) and Notice of Exercise under the 2017 Equity Incentive Plan (4)
  4.4
  Amendment No. 2 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (5)
  4.5
  Amendment No. 3 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan, as amended (6)
  5.1
  Opinion of Gracin & Marlow, LLP regarding Legality of Shares (7)
  23.1
  Consent of Friedman LLP, Independent Registered Public Accounting Firm (7)
  23.2
  Consent of Gracin & Marlow, LLP (contained in Exhibit 5.1) (7)
  24.1
  Power of Attorney (included on the signature page of this registration statement) (7)
  (1)
  Incorporated
  by reference to the Registrant's Form S-1, as amended (File No. 333-220368), filed with the Commission on October 25, 2017.
  (2)
  Incorporated
  by reference to the Registrant's Form S-8 (File No. 333-226884) filed with the Commission on August 16, 2018.
  (3)
  Incorporated
  by reference to the Registrant's Form S-8 (File No. 333-233760) filed with the Commission September 13, 2019.
  (4)
  Incorporated
  by reference to the Registrant's Form S-1, as amended (File No. 333-220368), filed with the Commission on September 7, 2017.
  (5)
  Incorporated
  by reference to the Registrant's Form S-8 (File No. 333-248759) filed with the Commission September 11, 2020.
  (6)
  Incorporated
  by reference to the Registrant's Current Report on Form 8-K (File No.
  001-38323
  ) filed
  with the Commission September 29, 2021.
  (7)
  Filed
  herewith
  7